Previous 10 | Next 10 |
Early observations about Omicron indicate that it is highly transmissible with mild symptoms and can evade mRNA vaccines. The article presents a scenario based on the available sketches of data, prognosticating how the pandemic may develop within the next two to three months. As m...
We are particularly enthused about a broad area that falls within the life science tools and services category, where we find many companies that are enabling innovative breakthroughs. Other growth themes in healthcare have either arisen or accelerated due to the COVID-19 pandemic. Th...
In making the case for less stringent regulations, pharmaceutical companies highlight the distinctions between list prices and net prices. The industry projects potential negative implications for patient access and R&D investments, and support in Congress has historically be limi...
The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....
Taking a look at how the expected Q3 ’21 sector revenue growth rates have changed since mid-August ’21 or the unofficial end of Q2 ’21 earnings season. Per Bespoke’s research, the S&P 500 has now reached “extremely oversold” levels, worse ...
Most of the market “data” everyone obsesses about is just noise, especially when it comes to economic data. We just finished another quarter during which a lot of things were supposedly newsworthy but somehow produced almost nothing in the way of major market movements. ...
iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) - $0.8321. 30-Day SEC Yield of 1.33% as of Aug 31. Payable Sep 30; for shareholders of record Sep 27; ex-div Sep 24. For further details see: iShares U.S. Pharmaceuticals ETF declares quarterly distribution of $0.8321
We’ve seen economic data in recent months moderate after record growth in the first half of 2021. In financials, the rise of many fintech companies and the growth of digital payments has really disrupted the traditional banking industry, creating new options for consumers. ...
Defensive stocks are often misunderstood. In recent years, even when they have delivered strong and steady earnings, returns have disappointed. After a period of underperformance for defensives, a broadening market can represent real opportunity. Beyond utilities, we believe that ...
Activists are circling the company and pressuring to unlock shareholder value. Stock still looks attractive from a valuation and near-term catalyst standpoint. We could see shares trade between $36 and $73 in the coming months. For further details see: Activist Spotlight...
News, Short Squeeze, Breakout and More Instantly...
iShares U.S. Pharmaceutical Company Name:
IHE Stock Symbol:
NYSE Market:
2024-07-12 08:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-22 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-31 20:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...